Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides
Lucia Kořínková, Veronika Pražienková, Lucie Černá, et al.
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review
Rodrigo Zamignan Carpi, Sandra Maria Barbalho, Kátia Portero Sloan, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8805-8805
Open Access | Times Cited: 86
Recent Advances in the Knowledge of the Mechanisms of Leptin Physiology and Actions in Neurological and Metabolic Pathologies
María E. Casado, Roberto Collado-Pérez, Laura M. Frago, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1422-1422
Open Access | Times Cited: 46
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zhikai Zheng, Zong Yao, Yiyang Ma, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 45
Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery
Inês Domingues, Isabelle Leclercq, Ana Beloqui
Journal of Controlled Release (2023) Vol. 363, pp. 415-434
Closed Access | Times Cited: 27
The Role of CTGF in Liver Fibrosis Induced in 3D Human Liver Spheroids
Sara Redenšek, Sander van Riet, Åsa Nordling, et al.
Cells (2023) Vol. 12, Iss. 2, pp. 302-302
Open Access | Times Cited: 15
Effectiveness of RESET care program: A real-world-evidence on managing non-alcoholic fatty liver disease through digital health interventions
Jayesh Soni, Neha Pathak, Mihir Gharia, et al.
World Journal of Hepatology (2025) Vol. 17, Iss. 1
Closed Access
The Reduced Gut Lachnospira Species Is Linked to Liver Enzyme Elevation and Insulin Resistance in Pediatric Fatty Liver Disease
Ching‐Chung Tsai, Min‐Hsi Chiu, Ho-Poh Kek, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3640-3640
Open Access | Times Cited: 4
Understanding Choline Bioavailability and Utilization: First Step Toward Personalizing Choline Nutrition
Ying Qi Goh, Guoxiang Cheam, Yulan Wang
Journal of Agricultural and Food Chemistry (2021) Vol. 69, Iss. 37, pp. 10774-10789
Closed Access | Times Cited: 30
Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis
Huan Xue, Hao-Jie Xing, B. Wang, et al.
Drug Design Development and Therapy (2023) Vol. Volume 17, pp. 1417-1432
Open Access | Times Cited: 10
What Is in a Name: from NAFLD to MAFLD and MASLD—Unraveling the Complexities and Implications
Mariana M. Ramírez-Mejía, Nahúm Méndez‐Sánchez
Current Hepatology Reports (2023) Vol. 22, Iss. 4, pp. 221-227
Closed Access | Times Cited: 10
Metabolic dysfunction-associated steatotic liver disease-induced changes in the antioxidant system: a review
Gabriela Svobodová, Martin Horní, Eva Velecká, et al.
Archives of Toxicology (2024)
Open Access | Times Cited: 3
Efficacy of Hot Tea Infusion vs. Ethanolic Extract of Moringa oleifera for the Simultaneous Treatment of Nonalcoholic Fatty Liver, Hyperlipidemia, and Hyperglycemia in a Murine Model Fed with a High-Fat Diet
Salma I. Cortes-Alvarez, Iván Delgado‐Enciso, Alejandrina Rodríguez‐Hernández, et al.
Journal of Nutrition and Metabolism (2024) Vol. 2024, pp. 1-15
Open Access | Times Cited: 3
Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials
Joel Yeh Siang Chen, Damien Chua, Carissa Odelia Lim, et al.
International Journal of Molecular Sciences (2022) Vol. 24, Iss. 1, pp. 158-158
Open Access | Times Cited: 15
Platelets in Non-alcoholic Fatty Liver Disease
Andrea Dalbeni, Marco Castelli, Mirko Zoncapè, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 14
Lactiplantibacillus plantarum DSM20174 Attenuates the Progression of Non-Alcoholic Fatty Liver Disease by Modulating Gut Microbiota, Improving Metabolic Risk Factors, and Attenuating Adipose Inflammation
José Ignacio Riezu‐Boj, Miguel Barajas, Tania Pérez, et al.
Nutrients (2022) Vol. 14, Iss. 24, pp. 5212-5212
Open Access | Times Cited: 12
Exploring autoantibodies as predictors of severe fibrosis or cirrhosis in metabolic dysfunction associated with steatotic liver disease
Mariam Ragheb, Micah Grubert Van Iderstine, Gerald Y. Minuk, et al.
Canadian Liver Journal (2024) Vol. 7, Iss. 2, pp. 291-298
Open Access | Times Cited: 2
Unravelling the complexities of non-alcoholic steatohepatitis: The role of metabolism, transporters, and herb-drug interactions
Ravi Adinarayan Somabattini, Sahla Sherin, Brian Siva, et al.
Life Sciences (2024) Vol. 351, pp. 122806-122806
Closed Access | Times Cited: 2
Emerging Treatment Options for Sarcopenia in Chronic Liver Disease
Yun Kim
Life (2021) Vol. 11, Iss. 3, pp. 250-250
Open Access | Times Cited: 17
Cisd2 Protects the Liver from Oxidative Stress and Ameliorates Western Diet-Induced Nonalcoholic Fatty Liver Disease
Yi‐Long Huang, Zhao‐Qing Shen, Chen‐Hua Huang, et al.
Antioxidants (2021) Vol. 10, Iss. 4, pp. 559-559
Open Access | Times Cited: 16
Resveratrol attenuates against high-fat-diet-promoted non-alcoholic fatty liver disease in rats mainly by targeting the miR-34a/SIRT1 axis
Mona N. BinMowyna, Nora A. AlFaris, Ekram A. Al-Sanea, et al.
Archives of Physiology and Biochemistry (2022) Vol. 130, Iss. 3, pp. 300-315
Closed Access | Times Cited: 11
Non-alcoholic Fatty Liver Disease and Gallstones: A Systematic Review.
Ethan Slouha, Stefan J Biput, Azeez Kuteyi, et al.
PubMed (2023) Vol. 15, Iss. 9, pp. e45027-e45027
Closed Access | Times Cited: 6
Evaluating the effect of basic fibroblast growth factor on the progression of NASH disease by inhibiting ceramide synthesis and ER stress-related pathways
Shahrzad Rahimi, Seyyed Abdolhamid Angaji, Ahmad Majd, et al.
European Journal of Pharmacology (2023) Vol. 942, pp. 175536-175536
Closed Access | Times Cited: 5
Therapeutic effect of autophagy induced by rapamycin versus intermittent fasting in animal model of fatty liver
Sara Adel Hosny, Mohammed Moustafa, Fatma Mahmoud Mehina, et al.
Folia Histochemica et Cytobiologica (2023)
Open Access | Times Cited: 5
Switch‐associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1
Qiaofeng Qian, Li Yang, Jiajun Fu, et al.
Hepatology (2021) Vol. 75, Iss. 6, pp. 1507-1522
Open Access | Times Cited: 13
Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs
Eleftheria Galatou, Elena A. Mourelatou, Sophia Hatziantoniou, et al.
Antioxidants (2022) Vol. 11, Iss. 6, pp. 1060-1060
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top